The SEC filings page for Rapport Therapeutics, Inc. (Nasdaq: RAPP) provides access to the company’s official regulatory disclosures as a clinical-stage biotechnology issuer. Rapport’s common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on The Nasdaq Global Market under the symbol RAPP, so its filings offer detailed information on its precision neuroscience business and capital markets activity.
Through this page, readers can review Form 10-K and Form 10-Q reports (when filed) for discussions of Rapport’s RAP technology platform, the development of RAP-219 for drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain, and additional programs in chronic pain, migraine, and hearing or vestibular disorders. These periodic reports also describe risk factors, research and development expenses, and other elements of the company’s operating profile.
Frequent Form 8-K filings from RAPP document material events such as positive Phase 2a trial results for RAP-219 in focal onset seizures, new data analyses presented at scientific meetings, public offerings of common stock under an effective shelf registration statement on Form S-3, and quarterly financial results and business updates. Some 8-Ks also summarize regulatory developments, including clinical holds, end-of-Phase 2 planning, and changes to at-the-market sales arrangements.
Investors can also use this page to locate information related to shareholder meetings and voting outcomes, as disclosed in 8-K items covering submissions of matters to a vote of security holders. Insider transaction reports on Form 4, when available, complement these filings by showing equity activity by directors and officers.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings, highlight clinical and financial milestones, and make it easier to understand how new disclosures may relate to Rapport’s RAP-219 program and broader precision neuroscience pipeline. Real-time updates from EDGAR help ensure that new RAPP filings, including 10-K, 10-Q, 8-K, and Form 4 submissions, are quickly accessible in one place.
At Rapport Therapeutics, Inc., Chief Operating Officer Cheryl Gault sold 7,925 shares of common stock at a weighted average price of $33.0364 per share and 2,075 shares at a weighted average price of $33.7556 per share on September 30, 2026. Both sales were made under a Rule 10b5-1 trading plan adopted on December 10, 2025.
Rapport Therapeutics, Inc. officer Cheryl Gault reported 10,000 common shares for sale, with an aggregate market value of $330,200. The approximate sale date is September 30, 2026. The shares are identified as Founders Shares acquired from the issuer on September 5, 2024, and Morgan Stanley Smith Barney LLC is named as broker.
Rapport Therapeutics, Inc. Chief Executive Officer Ceesay Abraham sold 2,210 shares of common stock on September 23, 2026, in three transactions: 1,952 shares at a weighted average price of $39.0523, 215 shares at a weighted average price of $39.8602, and 43 shares at $41.0500 per share. The sales were made under Rule 10b5-1 trading plans adopted on March 27, 2026. Abraham's reported indirect holdings included 81,729 shares through Ceesay Family Irrevocable Trust and 20,729 shares through Dorothy Ceesay Irrevocable Trust.
Rapport Therapeutics, Inc. (RAPP) reports that Chief Executive Officer and director Abraham Ceesay sold common stock in two open-market transactions on September 8, 2026 under pre-arranged Rule 10b5-1 trading plans adopted on March 27, 2026. He sold 7,141 shares at a weighted average price of $45.56 and 1,069 shares at a weighted average price of $46.01, for total reported sales of 8,210 shares. Following these transactions, indirect holdings in Rapport Therapeutics common stock include 81,729 shares held by the Ceesay Family Irrevocable Trust and 20,729 shares held by the Dorothy Ceesay Irrevocable Trust.
Rapport Therapeutics, Inc. (RAPP) reported that Chief Executive Officer and director Abraham Ceesay sold 18,921 shares of common stock on August 25, 2026 in an open-market transaction at a weighted average price of $49.5723 per share, pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. Following this sale, he directly holds 467,187 shares of common stock, and also has indirect ownership of 81,729 shares through the Ceesay Family Irrevocable Trust and 20,729 shares through the Dorothy Ceesay Irrevocable Trust.
Rapport Therapeutics, Inc. (RAPP) reported that Chief Development Officer Krishnaswamy Yeleswaram sold a total of 50,160 shares of common stock in open-market transactions on August 24–25, 2026. The sales were executed under a Rule 10b5-1 trading plan adopted on December 10, 2025, at weighted average prices around $50–$51 per share across multiple price ranges.
Rapport Therapeutics, Inc. (RAPP) has a notice under Rule 144 filed by officer Krishnaswamy Yeleswaram to sell 37,000 shares of common stock through Morgan Stanley Smith Barney LLC. The proposed sale references an aggregate market value of $1,825,210.00 and outstanding common shares of 47,978,286 on NASDAQ.
The shares to be sold were acquired upon the vesting of founders shares during the period from 06/09/2024 through 02/09/2025. In the past three months, separate 10b5-1 plan sales by the same person included 13,160 shares for $657,977.63 on 08/24/2026 and 404 shares for $20,159.60 on 08/19/2026.
Rapport Therapeutics, Inc. (RAPP) is the issuer of common stock that an officer, Krishnaswamy Yeleswaram, has notified for potential resale under Rule 144. The notice covers 11,472 shares of common stock, to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services.
The filing lists an approximate market value of $553,409.28 for these shares and an approximate number of shares of the same class outstanding of 47,978,286. During the past three months, a separate Rule 10b5-1 sale of 404 shares for $20,159.60 is reported. The securities to be sold were acquired upon the vesting of founders shares between June 9, 2024 and August 20, 2024.
Rapport Therapeutics, Inc. (RAPP) reported that Chief Development Officer Krishnaswamy Yeleswaram sold 404 shares of common stock on 2026-08-19 at $49.90 per share in an open-market transaction. After this sale, the officer directly held 246,022 shares. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.
Rapport Therapeutics, Inc. (RAPP) received a Form 144 notice indicating that officer Krishnaswamy Yeleswaram plans to sell up to 2,092 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an approximate sale date of 08/19/2026.
The shares were acquired upon vesting of restricted stock units between 06/09/2024 and 02/09/2025 and are described as Founders Shares. The filing lists an aggregate market value of about $102,528.92 for the planned sale and reports 47,978,286 shares of common stock outstanding.